Drug
ADI-PEG20
ADI-PEG20 is a pharmaceutical drug with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_2
4
80%
Phase Distribution
0
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
3
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(1)
Terminated(1)
Detailed Status
Recruiting3
Withdrawn1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 24 (80.0%)
Phase 31 (20.0%)
Trials by Status
recruiting360%
withdrawn120%
completed120%
Recent Activity
3 active trials
Showing 5 of 5
recruitingphase_3
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
NCT05317819
recruitingphase_2
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
NCT05842512
withdrawnphase_2
ADI-PEG20, Obesity and Prediabetes
NCT05829239
recruitingphase_2
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
NCT06034977
completedphase_2
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
NCT00450372
Clinical Trials (5)
Showing 5 of 5 trials
NCT05317819Phase 3
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
NCT05842512Phase 2
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
NCT05829239Phase 2
ADI-PEG20, Obesity and Prediabetes
NCT06034977Phase 2
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
NCT00450372Phase 2
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5